Sign inJoin waitlistJoin the waitlist

Nancy Chan

Clinical Research Director, Breast Cancer · NYU Grossman School of Medicine

Credentials: · · · ·

History

Breast Cancer · NYU Grossman School of Medicine
Present
NYU Grossman School of Medicine · NYU Grossman Long Island School of Medicine
Present
NYU Grossman School of Medicine
Present

New York Presbyterian Hospital
2011–2014
Robert Wood Johnson University Hospital
2010–2011
Renaissance School of Medicine at Stony Brook University
2004–2008

Research

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
ESMO Open · 2022 · 289 citations
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Clinical Cancer Research · 2019 · 202 citations
Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical…
Clinical Cancer Research · 2017 · First of 23 authors · 200 citations

JM
Jyoti Malhotra
9 papers
Janice Mehnert
8 papers
JA
Joseph Aisner
7 papers
Shridar Ganesan
7 papers
Ann Silk
6 papers
Mark Stein
6 papers
Deborah Toppmeyer
4 papers
Eugenia Girda
4 papers
AB
Adam Brufsky
3 papers
Bruce Haffty
3 papers
Gregory Riedlinger
3 papers
KH
Kim Hirshfield
3 papers

Grants

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $90.7K · New York University School of Medicine
1996–2029

Clinical trials

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Principal investigator · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2029
Breast Cancer Implementation Science Study With Educational Intervention
Principal investigator · Recruiting
NYU Langone Health
2025–2027
Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
Principal investigator · Active not recruiting · Phase 2
Nancy Chan, MD
2018–2027
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
Principal investigator · Terminated · Phase 1
Rutgers, The State University of New Jersey
2010–2016